News
FDA suspends license for chikungunya vaccine Ixchiq over serious safety concerns
The US Food and Drug Administration (FDA) announced late last week that it has suspended the license for French drugmaker Valneva's chikungunya vaccine, saying that continued administration of the vaccine to the public would pose a danger to health.
FDA does a 180, suspending use of Valneva's chikungunya vaccine
Less than three weeks after lifting a pause on the use of Valneva’s chikungunya vaccine Ixchiq, the FDA has done an about-face, banning the use of the shot in the United States. | Less than three weeks after lifting a pause on the use of Valneva’s chikungunya vaccine Ixchiq,
MedPage Today on MSN17h
In Abrupt Reversal, FDA Yanks Ixchiq Vaccine Over Safety Concern
According to the vaccine's maker, Valneva, the FDA based its decision to suspend the shot on four new serious adverse events ...
Earlier this month, the FDA backed off on a pause in shipments of the chikungunya vaccine Ixchiq to older adults. Now, the ...
The FDA had halted use in older adults while it investigated reports of side effects. The vaccine’s label now carries new warnings and restricts vaccination to individuals at high risk of infection.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback